AmSurg receives 'strong buy' rating for the short term — 5 key notes

Zacks analysts gave AmSurg a short term rating of "strong buy," according to American Trade Journal.

Here are five key notes:

1.  Eight analysts gave AmSurg a short term price target of $83.63.

2. AmSurg has a higher price target estimate of $95 and a lower price estimate of $54.

3. The shares closed down 0.31 percent on Mon., Sept. 14. The company is up 15.17 percent in the last three-month period.

4. The company has a 52-week high of $87.21 and a 52-week low of $47.68.

5. AmSurg has a market cap of $3.9 billion.

More articles on surgery centers:
HCA receives 'B+' credit rating — 4 notes
4 new joint venture ASCs — July & August 2015
Tenet shares fall 0.7% — 5 takeaways

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast